Pharmaceutical care of acute liver injury in a patient with colon cancer induced by irinotecan

doi:10.19803/j.1672-8629.20240009

Abstract

Abstract: Objective To explore the role of clinical pharmacists in the treatment of liver injury in tumor patients, and to provide reference for the involvement of clinical pharmacists in clinical practice. Methods Clinical pharmacists participated in the treatment of one case of acute liver injury caused by irinotecan in a colon cancer patient, analyzed the causes of acute liver injury, assessed the causal relationship between the drug and liver injury using the Roussel Uclaf Causality Assessment Method (RUCAM), and adjusted the treatment with liver-protecting drugs. Results By analyzing the correlation between acute liver injury and diseases and drugs, clinical pharmacists quickly recommended optimization of the treatment with liver-protecting drugs, and provided pharmaceutical care for the patient. After treatment, the patient’s liver function was significantly improved. Conclusion Prudent pharmacological monitoring of patients under chemotherapy by clinical pharmacists can help to reduce the incidence of adverse reactions, optimize the effect of drug therapy, and improve the level of rational clinical use of drugs.

Key words: irinotecan, liver injury, colon cancer, adverse drug reaction, pharmaceutical care, clinical pharmacist

CLC Number:

R994.11

LIN Yanxin, LIU Yanhui, DONG Jing, YAO Jiachen, LI Wenyan. Pharmaceutical care of acute liver injury in a patient with colon cancer induced by irinotecan[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 693-696.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.20240009

https://www.zgywjj.com/EN/Y2024/V21/I6/693

References

[1] YU SY, YAO Y.Expert Consensus on Prevention and Treatment of Cancer Drug-Related Liver Injury (肿瘤药物相关性肝损伤防治专家共识)[M]. Beijing: China Union Medical College Press, 2014.
[2] Technology Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association. Chinese guideline for diagnosis and management of drug - induced liver injury (2023 version)[J]. Chinese Journal of Hepatology(中华肝脏病杂志), 2023, 31(4): 355-384.
[3] LI XY, TANG JT, MAO YM.Incidence and risk factors of drug-induced liver injury[J]. Liver international, 2022, 42(9): 1999-2014.
[4] Chinese College of Surgeons. China guideline for diagnosis and comprehensive treatment of colorectal liver metastases (version 2023)[J]. Chinese Journal of Digestive Surgery(中华消化外科杂志), 2023, 22(1): 1-28.
[5] TURAL D, AKAR E, MEHMET AO, et al.Severe liver dysfunction and safe use of 5-fluorouracil leucovorin and oxaliplatin in one patient with metastatic colorectal carcinoma[J]. Journal of Cancer Research & Therapeutics, 2014, 10(3): 745-748.
[6] Chinese Medical Association.Guideline for primary care of drug-induced liver injury(2019)[J]. Chinese Journal of General Practitioners(中华全科医师杂志), 2020, 19(10): 868-875.
[7] DEVARBHAVI H, AITHAL G, TREEPRASERTSUK S, et al.Drug-induced liver injury: Asia pacific association of study of liver consensus guidelines[J]. Hepatology international, 2021, 15(2): 258-282.
[8] ZENG D.Angelica Polysaccharide Alleviated Liver Injury Induced by 5-Fluorouracil by Regulating NRF2/HO-1 Signaling Pathway[D]. Chongqing Medical University, 2022.
[9] ZORZI D, LAURENT A, PAWLIK TM, et al.Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases[J]. The British journal of surgery, 2007, 94(3): 274-286.
[10] WANG F, CHEN SC, CAO NY, et al.Effect of irinotecan combined with cetuximab on liver function and histology in patients with advanced colorectal cancer and liver metastasis[J]. Chinese Journal of Clinical Oncology and Rehabilitation(中国肿瘤临床与康复), 2016, 23(9): 1047-1050.
[11] HAN J, LIU J, YU Z, et al.Risk factors for irinotecan-induced liver injury: a retrospective multicentre cross-sectional study in China[J]. British Medical Journal Open, 2023, 13(6):e069794.
[12] LI J, CHEN B, XI WQ, et al.Drug-drug interactions and disease status are associated with irinotecan-induced hepatotoxicity: a cross-sectional study in Shanghai[J]. Journal of Clinical Pharmacology, 2022, 62(9): 1160-1169.
[13] National Center for Clinical Research of Infectious Disease. Expect consensus on the diagnosis and treatment of intrahepatic cholestasis (2021 edition)[J]. Chinese Journal of Hepatology(中华肝脏病杂志), 2022, 30(2): 137-146.
[14] TIAN YJ, WANG JP, LEI XP, et al.Effect of ursodeoxycholic acid on acute liver injury induced by antitumor drugs and its effect on T lymphocyte subsets[J]. Chinese Hepatology(肝脏), 2020, 25(1): 73-75.
[15] CHEN J.Observation on the effect of adenosylmethionine combined with ursodeoxycholic acid in the treatment of cholestatic drug-induced liver injury[J]. Zhejiang Practical Medicine(浙江实用医学), 2015, 20(4): 239-240.
[16] LI RR, LI M, GOU Y, et al.Clinical characteristics and risk factors of 113 cases of anti-neoplastic drug-induced liver injury[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(5): 505-510.
[17] Medical Affairs Department of the National Health Commission. Chinese protocol of diagnosis and treatment of colorectal cancer (2023 edition)[J]. Medical Journal of Peking Union Medical College Hospital(协和医学杂志), 2023, 14(4): 706-733.
[18] FOLPRECHT G, GRUENBERGER T, BECHSTEIN W, et al.Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)[J]. Annals of oncology, 2014, 25(5): 1018-1025.
[19] FANG WT, GU YH.Medication options for colorectal cancer with complications[J]. Chinese Journal of Colorectal Diseases(Electronic Edition)(中华结直肠疾病电子杂志), 2018, 7(5): 420-430.
[20] RAYMOND E, BOIGE V, FAIVRE S, et al.Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction[J]. Journal of Clinical Oncology, 2002, 20(21): 4303-4312.
[21] Guangdong Pharmaceutical Association.Expert consensus on the clinical application and adverse reaction management of platinum drugs[J]. Pharmacy Today(今日药学), 2019, 29(9): 577-585.
[22] DOROSHOW JH, SYNOLD TW, GANDARA D, et al.Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the national cancer institute organ dysfunction working group[J]. Seminars in Oncology, 2003, 30(4 Suppl 15): 14-19.